| Item | Cat. No. | Application | Isotype | 
| Anti-SARS-CoV-2 Spike RBD mAbs [Cilgavimab Biosimilar] (MABL-4523) | MABL-4523 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-PDCD1/CD279/PD1;CTLA4/CD152 mAbs [Cadonilimab Biosimilar] (MABL-4493) | MABL-4493 | ELISA, FACS, Functional assay, in vivo binding | G1;na, Kappa;Lambda | 
| Anti-CCR8/CKR-L1/CDw198 mAbs [Cafelkibart Biosimilar] (MABL-4494) | MABL-4494 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-Bacteria Proteins HU and IHF mAbs [Calpurbatug Biosimilar] (MABL-4495) | MABL-4495 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-ERBB2/CD340/HER2 mAbs [Calotatug Biosimilar] (MABL-4496) | MABL-4496 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-IL2RA/CD25 mAbs [Camidanlumab Biosimilar] (MABL-4497) | MABL-4497 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-IL18 mAbs [Camoteskimab Biosimilar] (MABL-4498) | MABL-4498 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-PDCD1/CD279/PD1 mAbs [Camrelizumab Biosimilar] (MABL-4499) | MABL-4499 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa | 
| Anti-IL1B mAbs [Canakinumab Biosimilar] (MABL-4500) | MABL-4500 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-SARS-CoV-2 RBD mAbs [Canrivitug Biosimilar] (MABL-4501) | MABL-4501 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda | 
| Anti-MUC1/PEM/EMA mAbs [Cantuzumab Biosimilar] (MABL-4502) | MABL-4502 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-VWF mAbs [Caplacizumab Biosimilar] (MABL-4503) | MABL-4503 | ELISA, FACS, Functional assay, in vivo binding | na, na | 
| Anti-CCL2/MCP1 mAbs [Carlumab Biosimilar] (MABL-4504) | MABL-4504 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-ENG/CD105 mAbs [Carotuximab Biosimilar] (MABL-4505) | MABL-4505 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-IL27 mAbs [Casdozokitug Biosimilar] (MABL-4506) | MABL-4506 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-ERBB2/CD340/HER2 mAbs [Caxmotabart Biosimilar] (MABL-4507) | MABL-4507 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-PDL1/CD274 mAbs [Cemavafusp Biosimilar] (MABL-4508) | MABL-4508 | ELISA, FACS, Functional assay, in vivo binding | na, Kappa | 
| Anti-TNFRSF8/CD30 mAbs [Brentuximab Biosimilar] (MABL-4477) | MABL-4477 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-IL12B/CLMFp40 mAbs [Briakinumab Biosimilar] (MABL-4478) | MABL-4478 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda | 
| Anti-KIT/CD117 mAbs [Briquilimab Biosimilar] (MABL-4479) | MABL-4479 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
      联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
